Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effekt och säkerhet av Teplizumab hos japanska deltagare med Steg 2 Typ 1-diabetes (KIBOU-T1D)

6 november 2026 uppdaterad av: Sanofi

Effektivitet och säkerhet för teplizumab vid behandlingen av japanska pediatriska och vuxna deltagare i åldern 8 till 34 år med steg 2 typ 1-diabetes: en multicenter, randomiserad, öppen etikett, kontrollerad studie.

This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment.

Teplizumab has been approved by FDA to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. The dose regimen of teplizumab in this study is consistent with the regimen approved by US FDA.

Given prior clinical studies conducted in Western countries, this design is appropriate to assess the efficacy, safety and tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of a 14-day IV infusion regimen of teplizumab in Japanese Stage 2 T1D participants aged 1 to 34 years.

Studieöversikt

Status

Aktiv, inte rekryterande

Intervention / Behandling

Detaljerad beskrivning

Total study duration is approximately 756 days.

Studietyp

Interventionell

Inskrivning (Faktisk)

5

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Fukuoka, Japan, 812-0025
        • Investigational Site Number : 3920017
      • Kyoto, Japan, 606-8507
        • Investigational Site Number : 3920016
      • Nagasaki, Japan, 852-8501
        • Investigational Site Number : 3920014
      • Osaka, Japan, 545-8586
        • Investigational Site Number : 3920004
      • Tokyo, Japan, 101-8309
        • Investigational Site Number : 3920020
      • Tokyo, Japan, 162-8666
        • Investigational Site Number : 3920003
    • Chiba
      • Ichikawa, Chiba, Japan, 272-0827
        • Investigational Site Number : 3920015
    • Gunma
      • Maebashi, Gunma, Japan, 371-8511
        • Investigational Site Number : 3920011
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 060-8543
        • Investigational Site Number : 3920006
    • Hyōgo
      • Kobe, Hyōgo, Japan, 650-0017
        • Investigational Site Number : 3920018
    • Ishikawa-ken
      • Kanazawa, Ishikawa-ken, Japan, 920-8641
        • Investigational Site Number : 3920009
    • Iwate
      • Yahaba, Iwate, Japan, 028-3695
        • Investigational Site Number : 3920007
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 222-0036
        • Investigational Site Number : 3920019
    • Saitama
      • Iruma, Saitama, Japan, 350-0495
        • Investigational Site Number : 3920001
    • Yamanashi
      • Chūō, Yamanashi, Japan, 409-3898
        • Investigational Site Number : 3920010

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

1 år till 34 år (Barn, Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Male or female Japanese participant, 1 (inclusive) to 34 years (inclusive) of age, at the time of signing the informed consent. Japanese: born in Japan or ethnic Japanese born outside of Japan, and a descendent of 4 ethnic Japanese grandparents who were all born in Japan.
  • Confirmed diagnosis of Stage 2 T1D based on following criteria:
  • Participant is positive for 2 or more T1D related auto-antibodies (confirmed by written medical history and/or obtained at study screening). The autoantibodies that are to be confirmed are anti-GAD (glutamic acid decarboxylase), anti-IA2 (insulinoma-associated antigen 2), anti-insulin, anti-ZnT8 (zinc transporter 8), and/or ICA (islet cell antibody).
  • Oral glucose tolerance test (OGTT) or blood HbA1c confirms the participant has dysglycemia without overt hyperglycemia.
  • Participant must be in good health (except for being Stage 2 T1D) as determined by medical e)valuation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG) XE " ECG " \f Abbreviation \t "electrocardiogram" .
  • Participant is up to date with routine age-appropriate immunizations according to current local specific guideline prior to randomization.
  • Female participants should use contraceptives consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • A female participant is considered fertile (woman of childbearing potential - WOCBP) from the time of menarche until becoming postmenopausal unless permanently sterile. Female participants are eligible to participate if one of the following conditions applies:
  • Is a woman of nonchildbearing potential (WONCBP) OR
  • Is a WOCBP and agrees to keep abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, or use other highly effective contraceptive method, from signing of the informed consent to at least 3 months and 2 weeks after randomization and agrees not to donate or cryopreserve eggs (ova, oocytes) for the purpose of reproduction during this period.

A WOCBP must have at least a negative highly sensitive pregnancy test within 48 hours before the administration of study intervention.

If a urine test cannot be confirmed as negative (eg, an ambiguous result), a blood pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

Participants are excluded from the study if any of the following criteria apply:

  • Any presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic (except Stage 2 T1D), hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
  • Participant has clinical signs and symptoms consistent with COVID19, eg, fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening. Participant who had severe course of COVID-19 (ie, hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).
  • For participant ≥18 years, blood donation of 400 mL within 12 weeks (male) or 16 weeks (female), 200 mL within 4 weeks or apheresis donation within 2 weeks before randomization; for participant <18 years, blood donation of any volume within 16 weeks before randomization; for any participant, blood transfusion (any volume) within 2 months before randomization.
  • Presence or history of drug hypersensitivity to any biologic medication, or clinically significant allergic disease as diagnosed and treated by a physician. Participants with known hypersensitivity to teplizumab or components of the teplizumab injection (including sodium phosphate, sodium chloride, polysorbate 80).
  • Participants with a history of active or latent or inactive tuberculosis (TB), including chest X-ray consistent with TB, regardless of treatment, or have a positive QuantiFERON-TB Gold test or T-SPOT TB test at screening.
  • At screening, participant has laboratory or clinical evidence of acute or clinically active infection with Epstein Barr virus (EBV), or history of infectious mononucleosis within 3 months before enrollment.
  • At screening, participant has laboratory or clinical evidence of acute or clinically active infection with cytomegalovirus (CMV).
  • Participants with a history of invasive opportunistic infections, such as histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, aspergillosis, irrespective of resolution.
  • Participants have other autoimmune diseases, except clinically stable autoimmune thyroid disease, or celiac disease.
  • Participants with a history of malignancy occurring within 5 years before randomization (except successfully treated carcinoma in situ of the cervix, or adequately treated nonmetastatic squamous cell or basal cell carcinoma of the skin).
  • Participants with fever (temperature ≥38.0°C) within 48 hours before randomization; or with chronic persistent or recurring infection(s) requiring active treatment with antibiotics, antiviral or antifungals within 4 weeks before randomization; or with other frequent recurrent infections deemed unacceptable as per Investigator's judgement.
  • If female, pregnancy (defined as positive blood or urine pregnancy test) or breast-feeding.
  • Participant has recent or planned vaccinations as follows:
  • Live vaccines: within 8 weeks before randomization, and/or within 54 weeks after randomization.
  • Non-live vaccines: any initial non-live vaccination within 2 weeks before randomization, and/or within 8 weeks after randomization.
  • Participant has a current or prior (within 30 days before randomization) treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, including high dose, inhaled, extensive topical, or systemic glucocorticoids.
  • Participant has a current or prior (within 30 days before randomization) treatment that is known to significantly influence glucose tolerance (anti-hyperglycemic agents, atypical antipsychotics, diphenylhydantoin, niacin etc.).
  • Participant has received any anti-CD3 (cluster of differentiation 3) antibody treatment (including teplizumab) before randomization.
  • Participant who has received any biologic therapy within five half-lives of the therapy or within 6 months before randomization whichever is longer, or plan to receive any biologic therapy within 6 weeks after randomization.
  • Any participant enrolled or having participated, in this or any other clinical study involving an investigational medicinal product (IMP) or in any other type of medical research and is still in the exclusion period according to applicable regulations (eg, having received an IMP of new active pharmaceutical ingredient (API) within 4 months or that of an approved API within 3 months before the administration of this study's IMP).
  • Participant has any of the following hematologic parameters before randomization:
  • Lymphocyte count <1.0 ×109/L.
  • Neutrophil count <1.5 ×109/L.
  • Platelet count <150 ×109/L.
  • Hemoglobin <100 g/L.
  • Participant has any of the following liver function test abnormalities before randomization:
  • AST >2 × ULN (upper limit normal).
  • ALT >2 × ULN.
  • Total bilirubin >1.5 × ULN with the exception of participants with the diagnosis of Gilbert's syndrome who may be eligible provided they have no other causes leading to hyperbilirubinemia.
  • Positive result on any of the following tests:
  • Hepatitis B surface antigen or hepatitis B core antibody confirmed by positive HBV-DNA (hepatitis B virus DNA).
  • Anti-hepatitis C virus antibody confirmed by positive HCV-RNA (hepatitis C virus RNA).
  • Human immunodeficiency virus antigen/ antibodies.
  • Positive SARS-CoV-2 test.
  • Participant who has contraindications or known allergy to both nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, or anti-histamines and in the opinion of the Investigator, cannot participate in the study.
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Teplizumab

Participants will receive Teplizumab via IV infusion

Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion

Andra namn:
  • SAR446681
  • Tzield
Inget ingripande: Control

Participants will receive no treatment in the control group

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Antal deltagare med stadium 3 typ 1 -diabetes baserat på amerikanska diabetesföreningskriterier
Tidsram: Från baslinjen upp till vecka 104
Från baslinjen upp till vecka 104
Byt från baslinjen i området under kurvan (AUC) av C-peptid
Tidsram: Från baslinjen till vecka 104
Från baslinjen till vecka 104
Change from baseline in AUC of endogenous insulin
Tidsram: From baseline up to Week 104
From baseline up to Week 104
Number of participants with TEAEs, SAEs, AEs leading to permanent study intervention- or study discontinuation; AEs of special interest; number of participants with clinically significant changes in vital signs, ECG, and/or safety laboratory test
Tidsram: Throughout the study, approximately 756 days

TEAE: treatment-emerged adverse event; SAE: serious adverse event; AE: adverse event

Throughout the study, approximately 756 days

Sekundära resultatmått

Resultatmått
Tidsram
Ändring från baslinjen i fastande plasmaglukos (FPG) från ett oralt glukostoleranstest
Tidsram: Från baslinjen till vecka 104
Från baslinjen till vecka 104
Ändring från baslinjen i 2-timmars plasmaglukos från ett oralt glukostoleranstest
Tidsram: Från baslinjen upp till vecka 104
Från baslinjen upp till vecka 104
Förändring från baslinjen för hemoglobin A1C (HBA1C)
Tidsram: Från baslinjen upp till vecka 104
Från baslinjen upp till vecka 104
Serumkoncentration av teplizumab
Tidsram: Från dag 1 till dag 28
Från dag 1 till dag 28
Antal deltagare med anti-läkemedelsantikroppar
Tidsram: Från baslinjen upp till vecka 104
Från baslinjen upp till vecka 104
Antal deltagare med neutraliserande antikroppar
Tidsram: Från baslinjen upp till vecka 104
Från baslinjen upp till vecka 104

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

25 juli 2025

Primärt slutförande (Beräknad)

6 mars 2028

Avslutad studie (Beräknad)

6 mars 2028

Studieregistreringsdatum

Först inskickad

20 januari 2025

Först inskickad som uppfyllde QC-kriterierna

20 januari 2025

Första postat (Faktisk)

24 januari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • ACT18487
  • U1111-1308-1324 (Registeridentifierare: ICTRP)
  • jRCT2031240637 (Registeridentifierare: JRCT)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera